Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2015-002921-20Phase 3Completed
Phase 3, open-label, single-arm trial of omiganan in papulopustular rosacea and rosacea, sponsored by Cutanea Life Sciences. Primary endpoint: Long-term safety of omiganan topical gel. Started Sep 2015; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2015-002921-20.